SHMT2 and cancer: Recently, major variability in cancer cell reliance on cytosolic (SHMT1) versus mitochondrial (SHMT2) serine-derived one-carbon metabolic flux was shown across tumors, suggesting the reduced folate carrier (RFC) as a marker for tumor sensitivity for drug targeting of the cytosolic pathway56.